@article {Davey:1 March 2000:1170-7690:295,
	author = "Davey P.J.",
	author = "Meyer E.",
	title = "The Cost Effectiveness of Misoprostol Prophylaxis Alongside Long Term Nonsteroidal Anti-Inflammatory Drugs: Implications of the MUCOSA Trial",
	journal = "PharmacoEconomics",
	volume = "17",
	year = "1 March 2000",
	abstract = "<B>Objective:</B> This study considered the cost effectiveness of misoprostol prophylaxis for nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal damage, using data from the Misoprostol Ulcer Complications Outcomes Safety Assessment (MUCOSA) trial. The initial aim was to gain listing of misoprostol on the Australian National Formulary.<P></P><B>Design:</B> The economic evaluation followed a 2-stage approach in considering the cost effectiveness of misoprostol, a &#145;within-trial&#146; analysis followed by a simple modelled analysis which explored the implications of the trial results for life-years saved beyond the trial setting. The perspective of the evaluation is that of the healthcare system.<P></P><B>Setting:</B> Three different populations were considered: the total trial population; patients with a history of peptic ulcer disease; and patients over 65 years of age.<P></P><B>Study population:</B> Patient data were taken from the MUCOSA trial, which involved 8843 patients receiving continuous NSAID therapy for the control of rheumatoid arthritis.<P></P><B>Interventions:</B> Misoprostol plus any NSAID therapy was compared with placebo (no misoprostol) plus any NSAID therapy.<P></P><B>Main outcome measures and results:</B> The study found the incremental cost per definite serious gastrointestinal complication avoided with misoprostol was 39 603 Australian dollars ($A) for the total trial population, $A5599 for patients with a history of peptic ulcer disease and $A35 405 for patients over 65 years of age. The incremental cost per life-year saved with misoprostol was $A41 866 for the whole group, $A6244 for patients with a history of peptic ulcer disease and $A40 322 for patients over 65 years of age.<P></P><B>Conclusions:</B> The study found misoprostol to be cost effective in this setting.",
	pages = "295-304(10)",
	url = "http://www.ingentaconnect.com/content/adis/pec/2000/00000017/00000003/art00007"
}